Introduction
============

Despite significant improvement in treatment strategies in recent years, ischemic heart disease (IHD) remains the leading cause of morbidity and mortality in both the developed [@B1] and developing countries [@B2]. Studies from recent decades have confirmed that oxidative stress plays an important role in the pathogenesis and progression of various cardiovascular diseases [@B3]-[@B5], including IHD. Oxidative stress is characterized by excessive reactive oxygen species (ROS) production and reduced cellular antioxidant activity, leading to membrane lipid peroxidation and mitochondrial dysfunction [@B6]. If oxidative insult persists, programmed cell death will be initiated partially through the mitochondrial pathway, causing the loss of functional cardiomyocytes. Therefore, treatment strategies with the potential to prevent oxidative stress are considered valuable for patients with IHD [@B7], [@B8].

Levocarnitine is a naturally occurring essential co-factor of fatty acid metabolism that is synthesized endogenously or obtained from dietary sources [@B9]. Physiologically, levocarnitine transports free fatty acids into the mitochondria, increasing the preferred substrate for oxidative metabolism in the heart [@B10]. As β-oxidation of fatty acids is the major biogenesis process of the heart, and metabolic and energy dysfunction are acknowledged to play key roles in the pathogenesis of various cardiovascular diseases [@B11], [@B12], it is reasonable to hypothesize that levocarnitine supplementation may benefit IHD patients, perhaps by restoring energy and metabolic functions. Indeed, previous human studies suggested that levocarnitine supplementation was associated with significantly reduced mortality in patients experiencing acute myocardial infarction [@B13]-[@B15]. Although some early experimental studies reported that the protective effects of levocarnitine in IHD patients were related to the attenuation of oxidative stress injury in the myocardium [@B16], [@B17], the exact mechanisms involved are still not fully understood.

Oxidative stress is mainly caused by excessive accumulation of ROS, which include hydrogen peroxide (H~2~O~2~), superoxide anions (O~2~-•), and hydroxyl radicals (•OH). H~2~O~2~ is a major component of ROS and is used extensively as an inducer in oxidative stress models, including many previous studies that evaluated the potential protective effects of levocarnitine against oxidative stress [@B18]-[@B20]. As an inducer of oxidative stress, H~2~O~2~ does not initiate lipid peroxidation or oxidize DNA or amino acids on its own, but may cause such damage by inducing oxidative stress [@B21], [@B22]. Therefore, the aim of the current study was investigating the potential protective effects of levocarnitine pretreatment on H~2~O~2~-induced oxidative stress in H9c2 rat cardiomyocytes *in vitro*, in particular, its effect on mitochondrial dysfunction and apoptosis.

Methods
=======

H9c2 rat cardiomyocyte culture and H~2~O~2~ treatment
-----------------------------------------------------

H9c2 embryonic rat heart-derived cells were obtained from American Type Culture Collection (Manassas, VA, USA). Cells were maintained in Dulbecco\'s modified Eagle\'s medium supplemented with 10% v/v fetal bovine serum (Beyotime Institute of Biotechnology, Haimen, China) and penicillin (100 U/mL)/streptomycin (100 μg/mL; both from Beyotime Institute of Biotechnology) at 37°C in a humidified atmosphere containing 5% CO~2~.

We first determined the appropriate concentration of H~2~O~2~ (Sigma-Aldrich, St Louis, MO, USA) for mimicking oxidative stress-induced injury in cardiomyocytes. In the preliminary study, H9c2 cells were treated with 200, 400, 600, 800, 1000, and 2000 μM H~2~O~2~ for 12 hours. We defined the appropriate H~2~O~2~ concentration as the lowest concentration that would lead to substantially reduced (about 50%) H9c2 cell viability when cells were treated for a relatively long duration, such as 12 hours. Viability was decreased in about 57% of H9c2 cells following 12-hour treatment with 200 μM H~2~O~2~. Therefore, we treated H9c2 cells with 200 μM H~2~O~2~ for 12 hours to establish the oxidative stress-induced injury model in cardiomyocytes; selection of the H~2~O~2~ concentration was also consistent with that of previous studies [@B19], [@B20].

Then, we evaluated the potential protective effects of levocarnitine (Sigma-Aldrich) against oxidative stress-induced injury in H9c2 cardiomyocytes through pretreatment with 10, 50, 100, 200, 500, 1000, 1500, or 2000 μM levocarnitine 1 hour prior to H~2~O~2~ exposure. We selected the three most effective concentrations for subsequent analyses.

Therefore, this study comprised six groups: (1) control: cells cultured under normal incubation conditions; (2) levocarnitine: cells treated with 200 μM levocarnitine for 1 hour without H~2~O~2~ exposure; (3) H~2~O~2~ model: cells exposed to H~2~O~2~ without levocarnitine pretreatment; (4\~6) levocarnitine pretreatment: cells pretreated with three different concentrations of levocarnitine 1 hour prior to H~2~O~2~ exposure.

Determination of cell viability
-------------------------------

Cell viability was assessed using Cell Counting Kit-8 (Sigma-Aldrich) according to the manufacturer\'s instructions. Briefly, H9c2 cells from the different treatment groups were seeded in 96-well plates at 10^3^ cells/well (10^4^ cells/mL, 100 μL/well) and 10 μL CCK-8 solution was administered into each well to determine cell viability. After 4-hour incubation at 37°C, the absorbance in each well was detected at 450 nm (reference 650 nm) using a microplate reader (Tecan GENios, Austria). Each experiment was repeated five times and the data were expressed as a percentage of the control.

Determination of intracellular ROS
----------------------------------

On its own, the fluorescent probe 29, 79-dichlorofluorescein diacetate (DCFH-DA) is non-fluorescent, and can cross cell membranes freely. Esterases hydrolyze intracellular DCFH-DA to produce DCFH, and intracellular ROS can oxidize the non-fluorescent DCFH to generate fluorescent 29, 79-dichlorofluorescein (DCF). Intracellular ROS in H9c2 cells were thus detected based on the fluorescence intensity of DCF in a fluorometer using an ROS detection kit according to the manufacturer\'s instructions (Beyotime Institute of Biotechnology). Briefly, cells were washed twice with phosphate-buffered solution (PBS) after treatment, and then the ROS detection solution was added. Cells were stained at 37°C in the dark for 20 min and visualized by fluorescence microscopy (Leica, Germany). Fluorescence was read on a confocal laser scanning microscope (TCS SP5 AOBS, Leica) at 504 nm excitation and 524 nm emission wavelengths. Fold-increases in ROS level were determined by comparison with the control group.

Measurement of lactate dehydrogenase activity
---------------------------------------------

Lactate dehydrogenase (LDH) activity was measured as LDH released in the culture medium. Briefly, 0.2 mL culture medium from each group was obtained after treatment and assayed for LDH activity using commercial kits (Beyotime Institute of Biotechnology) and a microplate reader (Tecan GENios) according to the manufacturer\'s instruction.

Determination of malondialdehyde, superoxide dismutase, and glutathione peroxidase activity
-------------------------------------------------------------------------------------------

After treatment, cells from each group were washed with cold PBS three times, harvested with 0.25% trypsin, and centrifuged at 1000 ×*g* for 10 min. The supernatant was discarded and the cell pellet sonicated in cold PBS. After centrifugation (800 ×*g*, 5 min), the supernatant was immediately evaluated for malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) cellular activity using commercial kits (Beyotime Institute of Biotechnology) with a spectrophotometer according to the manufacturer\'s protocols. The protein content of the cell homogenates was determined using a bicinchoninic acid assay according to the kit instructions.

Measurement of mitochondrial transmembrane potential
----------------------------------------------------

We used 5,5\',6,6\'-tetrachloro-1,1\',3,3\'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1; Sigma-Aldrich) to determine changes in mitochondrial transmembrane potential (ΔΨm). JC-1 (10 μL; 200 μM; final concentration 2 μM) was added to H9c2 cells on coverslips, incubated for 45 min in the dark, and washed twice with PBS. JC-1-labeled cells were observed under a confocal laser scanning microscope (TCS SP5 AOBS). JC-1 fluorescence was measured from a single excitation wavelength (490 nm) with dual emission (shift from green at 530 nm to red at 590 nm). Loss of mitochondrial ΔΨm is presented as the relative ratio of green to red fluorescence.

Measurement of intracellular adenosine triphosphate
---------------------------------------------------

Cellular adenosine triphosphate (ATP) was measured by an ATP Bioluminescence Assay Kit according to the manufacturer\'s instructions (Beyotime Institute of Biotechnology). After treatment, cells were washed with PBS, lysed, and the supernatant collected. Proteins (10 μg/20 μL) were added to a white OptiPlate (PerkinElmer, Waltham, MA, USA) and the reaction initiated by adding reconstituted reagent. Luminescence was measured using a microplate reader (Tecan GENios).

Determination of cardiomyocyte apoptosis
----------------------------------------

Apoptosis was measured with a commercial kit (Beyotime Institute of Biotechnology) as recommended by the manufacturer. Approximately 10^5^ H9c2 cells were stained for 15 min with annexin V-fluorescein isothiocyanate and propidium iodide at room temperature in the dark. Apoptosis was analyzed by flow cytometry with a cytometer (BD LSRII; BD Biosciences, San Diego, CA, USA). Distribution of apoptotic cells was analyzed using FlowJo 7.6 software (TreeStar, Ashland, OR, USA).

Western blotting
----------------

Total proteins from H9c2 cells were extracted, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and detected using an ECL Western Blotting Detection Kit (GE Healthcare, UK). Antibodies against β-actin, Bcl-2, Bax, and cytochrome C were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Digital images were analyzed for densitometry using Image Lab™ Software Version 3.0 (Bio-Rad, Hercules, CA, USA).

Statistical analyses
--------------------

SPSS 17.0 (SPSS Inc., CA, USA) was used for statistical analysis. Results are expressed as the mean ± SEM. Statistical differences among groups were analyzed by two-way analysis of variance (H~2~O~2~ × Levocarnitine), followed by the least significant difference test. Statistical significance was indicated when *p*\< 0.05.

Results
=======

Levocarnitine pretreatment protected cardiomyocytes from H~2~O~2~-induced decrease in cell viability
----------------------------------------------------------------------------------------------------

To evaluate the potential protective effects of levocarnitine against oxidative stress-induced injury in H9c2 cardiomyocytes, we investigated whether 1-hour levocarnitine pretreatment would attenuate H~2~O~2~-induced cell death. Pretreatment with 10 μM levocarnitine significantly preserved H9c2 cardiomyocyte viability as compared with the control group that received no levocarnitine (*p*\< 0.05, **Figure [1](#F1){ref-type="fig"}**). The protective effects of levocarnitine pretreatment on cell viability were dose-dependent, with 200 μM levocarnitine achieving the strongest effect. Therefore, we used 50, 100, and 200 μM levocarnitine in subsequent analyses to observe the potential dose-dependent effect of levocarnitine.

Levocarnitine pretreatment attenuated H~2~O~2~-induced LDH release
------------------------------------------------------------------

To confirm the protective effects of levocarnitine pretreatment against oxidative stress-induced cell injury, we measured LDH release in each group. Plasma LDH activity reflects the cell membrane damage caused by oxidative stress. LDH activity in the culture medium of the model group was significantly higher than that in the control group (*p*\< 0.05, **Figure [2](#F2){ref-type="fig"}**), suggesting that 12-hour H~2~O~2~ exposure led to severe cell injury. It appeared that levocarnitine pretreatment significantly reduced the levels of LDH activity in a dose-dependent manner.

Levocarnitine pretreatment reduced H~2~O~2~-induced oxidative stress
--------------------------------------------------------------------

To evaluate whether the protective effects of levocarnitine on H9c2 cardiomyocytes were related to reduced oxidative stress, we evaluated the effects of levocarnitine pretreatment on intracellular ROS in H9c2 cells. H~2~O~2~ exposure increased cellular ROS production significantly, reflected by the higher DCF-DA fluorescence intensity in the model group compared with the control group (*p*\< 0.05, **Figure [3](#F3){ref-type="fig"}**).

Interestingly, we found that levocarnitine pretreatment reduced intracellular ROS, suggesting that levocarnitine may reduce the ROS production induced by H~2~O~2~ exposure. As excessive ROS may lead to severe cellular membrane damage through peroxidative lipid injury, we explored whether levocarnitine pretreatment reduced MDA activity, which is a marker of the extent of lipid peroxidation. Levocarnitine pretreatment was associated with significantly reduced MDA activity, confirming that levocarnitine alleviated H~2~O~2~-induced lipid peroxidation (**Figure [4](#F4){ref-type="fig"}A**). Lastly, we attempted to clarify whether levocarnitine pretreatment affected intracellular antioxidant activity. Levocarnitine pretreatment partially ameliorated the loss of cellular antioxidants caused by H~2~O~2~ exposure, including SOD and GSH-Px, and these effects appeared to be dose-dependent (**Figure [4](#F4){ref-type="fig"}B and [4](#F4){ref-type="fig"}C**).

Levocarnitine pretreatment attenuated H~2~O~2~-induced loss of mitochondrial ΔΨm and ATP
----------------------------------------------------------------------------------------

As mitochondrial ΔΨm is fundamental to the maintenance of mitochondrial physiological function [@B23], we observed the effect of levocarnitine on mitochondrial ΔΨm. JC-1 staining revealed significant loss of mitochondrial ΔΨm in the model group (**Figure [5](#F5){ref-type="fig"}**). Pretreatment with 100 and 200 μM levocarnitine significantly attenuated mitochondrial ΔΨm loss (*p*\< 0.05), although the effect of 50 μM levocarnitine was not statistically significant. To evaluate the protective effects of levocarnitine on mitochondrial function, we measured intracellular ATP in each group. Cellular ATP was significantly reduced in the model group compared with the control group (*p*\< 0.05, **Figure [6](#F6){ref-type="fig"}**), indicating that oxidative stress induced by H~2~O~2~ exposure caused significant cellular energy metabolism dysfunction. Notably, levocarnitine pretreatment partially prevented the oxidative stress-induced loss of ATP in cardiomyocytes dose-dependently, possibly through the preservation of mitochondrial function.

Levocarnitine pretreatment prevented H~2~O~2~-induced apoptosis by regulating key molecules in the intrinsic apoptotic pathway
------------------------------------------------------------------------------------------------------------------------------

As oxidative stress and related mitochondrial dysfunction may lead to cardiomyocyte apoptosis, which has been recognized as playing a key role in the pathogenesis and progression of various cardiovascular diseases [@B24], we investigated the effects of levocarnitine on H~2~O~2~-induced cardiomyocyte apoptosis. In this study, cells were distinguished as living (annexin V-/propidium iodide \[PI\]-), early apoptotic (annexin V+/PI-), late apoptotic (annexin V+/PI+), and necrotic (annexin V-/PI+). Flow cytometry analyses (**Figure [7](#F7){ref-type="fig"} and Table [1](#T1){ref-type="table"}**) indicated that levocarnitine pretreatment was associated with significantly reduced early- and the late-phase oxidative stress-induced apoptosis, perhaps dose-dependently. Additionally, there remained more living cells in the levocarnitine-pretreated groups as compared with the model group.

To investigate the potential molecular mechanisms involved, we performed western blotting to explore the effects of levocarnitine pretreatment on the related proteins in the intrinsic apoptotic pathway. Levocarnitine pretreatment restored protein levels of the anti-apoptotic molecule Bcl-2 and reduced expression of the apoptotic molecule Bax (**Figure [8](#F8){ref-type="fig"}**). Levocarnitine pretreatment also attenuated cytochrome C release dose-dependently. These results suggest that levocarnitine may partially prevent oxidative stress-induced cardiomyocyte apoptosis through the intrinsic apoptotic pathway.

Discussion
==========

We created a model of H~2~O~2~-induced oxidative stress in H9c2 cardiomyocytes and found that H~2~O~2~ exposure led to significant activated oxidative stress in the cells, which was characterized by reduced cell viability, increased intracellular ROS and lipid peroxidation, and reduced intracellular antioxidant activity. Mitochondrial dysfunction was also observed following H~2~O~2~ exposure, reflected by the loss of mitochondrial ΔΨm and intracellular ATP. These pathophysiological processes led to apoptosis by activation of the intrinsic apoptotic pathway. More importantly, the 1-hour levocarnitine pretreatment significantly attenuated the above H~2~O~2~-induced oxidative injury, preserved mitochondrial function, and partially prevented apoptosis during the oxidative stress reaction. The potential protective effects of levocarnitine pretreatment against oxidative stress-related injury in H9c2 cells appeared dose-dependent. These results expand our insight into the potential benefits of levocarnitine for patients with oxidative stress-related cardiovascular diseases, such as IHD.

Previous studies have reported the protective effects of levocarnitine against oxidative stress-related injury. Calo *et al*. found that in human endothelial cells, levocarnitine stimulated gene and protein expression of heme oxygenase-1 and endothelial nitric oxide synthase, two well-known antioxidants upregulated during oxidative stress [@B16]. These findings highlight the possibility that levocarnitine supplementation may be protective against oxidative stress-related cardiovascular risk factors and myocardial damage [@B16]. A subsequent study of neonatal cardiomyocytes also suggested that levocarnitine protects cardiomyocytes from doxorubicin-induced apoptosis, in part through the prostacyclin and peroxisome proliferator-activated receptor alpha signaling pathways [@B17]. As oxidative stress plays an important role in doxorubicin-induced cardiomyopathy [@B25], these results also support the premise that the cardioprotective effects of levocarnitine are at least partially dependent on its action against the oxidative stress reaction. In addition to cardiovascular system studies, evidence from human peripheral blood lymphocytes [@B26], human retinal pigment epithelial cells [@B27], and human hepatocytes [@B28] also support the potential antioxidative effects of levocarnitine. Our results confirmed the above findings by demonstrating that levocarnitine pretreatment preserved cell viability, reduced ROS, increased antioxidant activity, and attenuated lipid peroxidation in H9c2 cardiomyocytes exposed to H~2~O~2~.

It is well established that the mitochondria play a key role in energy metabolism and biogenesis in cardiomyocytes [@B11]. Moreover, mitochondrial dysfunction is an important feature during the pathophysiological process of oxidative stress [@B12]. Considering levocarnitine is located between the inner and outer mitochondrial membranes, and physically functions as a free fatty acid transporter into the mitochondria for β-oxidation [@B29], it appears reasonable to propose that the maintenance of mitochondrial function and energy metabolism by levocarnitine partially mediates the potential protective effects of levocarnitine during oxidative stress. Although previous studies have suggested the potential benefit of levocarnitine supplementation to mitochondrial function and energy metabolism [@B30], [@B31], our results confirm that these effects are the means by which levocarnitine pretreatment attenuates oxidative stress-induced damage in H9c2 cardiomyocytes. Indeed, our study indicated that levocarnitine pretreatment preserved cellular ATP and significantly prevented the loss of mitochondrial ΔΨm, thereby preserving the cardiomyocyte energy supply during oxidative stress. These results are consistent with previously reported findings [@B32].

In addition to energy metabolism, another important function of the mitochondria is the regulation of apoptosis. During oxidative stress, excessive ROS production, most likely from both H~2~O~2~ treatment and subsequent mitochondrial damage, may create a vicious cycle by leading to severe mitochondrial membrane damage, loss of mitochondrial ΔΨm, and subsequent cytochrome C release, thus initiating the intrinsic apoptotic pathway [@B33]. Moreover, some apoptotic process regulatory proteins, including Bcl-2 and Bax, are located in the mitochondrial membrane. Imbalance of these regulatory proteins also has an important effect on apoptosis [@B34]. Our findings demonstrate that levocarnitine pretreatment may also attenuate oxidative stress-induced cardiomyocyte apoptosis via regulation of the intrinsic apoptotic pathway and Bcl-2 family proteins. As loss of functional cardiomyocytes is one of the important mechanisms in the pathogenesis and progression of cardiovascular diseases [@B35], the benefits of levocarnitine against oxidative stress-induced cardiomyocyte injury may also include attenuation of apoptosis.

In conclusion, our *in vitro* study indicated that levocarnitine pretreatment may protect cardiomyocytes from oxidative stress-related damage by inhibiting ROS production, increasing intracellular antioxidants, preserving mitochondrial function, and attenuating apoptosis. These results may partially explain the clinical benefit of levocarnitine in patients with prior myocardial infarction [@B15]. These results require verification in animal studies in the future.

![Effects of 1-hour levocarnitine pretreatment on H~2~O~2~-induced loss of H9c2 cell viability. LC, Levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). ^\#^*p*\< 0.05 compared with the group with no pretreatment; \**p*\< 0.01 compared with the group with no pretreatment.](ijmsv11p1107g001){#F1}

![Effects of 1-hour levocarnitine pretreatment on LDH activity in each group. LDH, Lactate dehydrogenase; LC, levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model group.](ijmsv11p1107g002){#F2}

![Effects of 1-hour levocarnitine pretreatment on H~2~O~2~-induced ROS accumulation in H9c2 cells. (A) Representative images of ROS staining. Cells with green fluorescence indicate elevated intracellular ROS. (B) Quantitative analysis of ROS staining. ROS, Reactive oxygen species; LC, levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model group.](ijmsv11p1107g003){#F3}

![Effects of 1-hour levocarnitine pretreatment on (A) MDA, (B) SOD, and (C) GSH-Px activity in each group. MDA, Malondialdehyde; SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; LC, levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model group.](ijmsv11p1107g004){#F4}

![Effects of 1-hour levocarnitine pretreatment on H~2~O~2~-induced loss of mitochondrial ΔΨm in H9c2 cells (JC-1 staining). (A) Representative images of JC-1 staining. (B) Quantitative analysis of JC-1 staining. LC, Levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model group.](ijmsv11p1107g005){#F5}

![Effects of 1-hour levocarnitine pretreatment on cellular ATP. LC, Levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model group.](ijmsv11p1107g006){#F6}

![Representative images of the effects of 1-hour levocarnitine pretreatment on H~2~O~2~-induced apoptotic cell distribution in H9c2 cells. LC, Levocarnitine.](ijmsv11p1107g007){#F7}

![Effects of 1-hour levocarnitine pretreatment on protein levels of apoptosis-related molecules in H9c2 cells. (A) Representative western blots. (B) Quantitative analyses for Bcl-2. (C) Quantitative analyses for Bax. (D) Quantitative analyses for cytochrome C. LC, Levocarnitine. Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model group.](ijmsv11p1107g008){#F8}

###### 

Effects of levocarnitine pretreatment on H9c2 cardiomyocyte apoptosis.

  --------------------------------------------------------------------------------------
                  Viable cells\         Early-phase apoptosis\   Late-phase apoptosis\
                  (annexin V-/PI-, %)   (annexin V+/PI-, %)      (annexin V+/PI+, %)
  --------------- --------------------- ------------------------ -----------------------
  **Control**     94.3 ± 3.44^\#^       1.06 ± 0.05^\#^          2.05 ± 0.78^\#^

  **LC only**     93.12 ± 4.01^\#^      1.81 ± 0.46^\#^          2.69 ± 0.43^\#^

  **Model**       64.79 ± 2.86\*        18.41 ± 1.68\*           14.89 ± 2.69\*

  **LC-50 μM**    75.84 ± 6.92\*^\#^    13.47 ± 3.99\*^\#^       10.08 ± 4.08\*^\#^

  **LC-100 μM**   80.03 ± 5.17\*^\#^    9.97 ± 4.63\*^\#^        6.93 ± 3.55\*^\#^

  **LC-200 μM**   89.25 ± 7.32\*^\#^    5.76 ± 2.21\*^\#^        3.42 ± 1.71\*^\#^
  --------------------------------------------------------------------------------------

Data presented are the mean ± SEM (*n* = 4\~6 per group). \**p*\< 0.05 compared with the control group;^\#^*p*\< 0.05 compared with the model groups. LC, Levocarnitine; FITC, fluorescein isothiocyanate; PI, propidium iodide.
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